Brought to you by 
Takeda partners with Cour for celiac disease immune therapy
23 Oct 2019
Executive Summary
Takeda Pharmaceutical Co. Ltd. and Cour Pharmaceutical Development Co. Inc. partnered to develop treatments for celiac disease and other gastrointestinal conditions based on Cour's immune-based technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda partners with Cour for celiac disease immune therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice